Trial Profile

A phase I trial of LX-101 in patients with advanced, pretreated solid and hematologic cancers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 29 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LX 101 (Primary)
Indications Haematological malignancies; Solid tumours
Focus Adverse reactions

Most Recent Events

26 Feb 2024 Results published in the Lirum Therapeutics Media Release.
26 Feb 2024 According to a Lirum Therapeutics media release, the data from this trial will be presented at the 2024 European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies Congress in Paris, France on Monday, February 26th at 5:15 PM CET (11:15 ET).
05 Jun 2023 Results presented in a Lirum Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com